Neurocrine Biosciences, Inc.
Hedge Funds Holdings
Last updated:
Neurocrine Biosciences, Inc.‘s stocks are currently a part of 420 hedge funds’ portfolios, which represents 90.73% of the total amount of its stocks outstanding. This makes up a total of 88.55M shares of Neurocrine Biosciences, Inc.. Compared to the previous quarter, the number fell by -0.73% or -649.16K shares fewer. As for the holding position changes, 36.67% (154) of current hedge fund investors increased the number of shares held, 36.67% (154) of current holders sold a part of the shares held, and 10.48% (44) closed the holdings completely. 57 hedge funds are new holders of Neurocrine Biosciences, Inc. stock in Q2 2022, it is 13.57% of total holders.
Hedge funds holding Neurocrine Biosciences (Q3 2017 – Q2 2022)
| Q3 2017 | 222 |
|---|---|
| Q4 2017 | 265 |
| Q1 2018 | 261 |
| Q2 2018 | 271 |
| Q3 2018 | 340 |
| Q4 2018 | 321 |
| Q1 2019 | 320 |
| Q2 2019 | 296 |
| Q3 2019 | 324 |
| Q4 2019 | 381 |
| Q1 2020 | 362 |
| Q2 2020 | 407 |
| Q3 2020 | 406 |
| Q4 2020 | 390 |
| Q1 2021 | 401 |
| Q2 2021 | 391 |
| Q3 2021 | 378 |
| Q4 2021 | 388 |
| Q1 2022 | 411 |
| Q2 2022 | 420 |
Hedge funds changes in Neurocrine Biosciences positions (Q3 2017 – Q2 2022)
| Q3 2017 | 31 | 99 | 51 | 27 | 14 |
|---|---|---|---|---|---|
| Q4 2017 | 66 | 81 | 91 | 24 | 3 |
| Q1 2018 | 35 | 103 | 87 | 37 | -1 |
| Q2 2018 | 41 | 97 | 95 | 30 | 8 |
| Q3 2018 | 90 | 93 | 113 | 20 | 24 |
| Q4 2018 | 70 | 110 | 109 | 88 | -56 |
| Q1 2019 | 48 | 140 | 96 | 48 | -12 |
| Q2 2019 | 35 | 118 | 101 | 51 | -9 |
| Q3 2019 | 60 | 123 | 104 | 31 | 6 |
| Q4 2019 | 105 | 135 | 102 | 39 | 0 |
| Q1 2020 | 44 | 137 | 139 | 58 | -16 |
| Q2 2020 | 86 | 169 | 108 | 36 | 8 |
| Q3 2020 | 68 | 185 | 109 | 67 | -23 |
| Q4 2020 | 59 | 140 | 149 | 72 | -30 |
| Q1 2021 | 73 | 156 | 126 | 59 | -13 |
| Q2 2021 | 46 | 165 | 127 | 52 | 1 |
| Q3 2021 | 32 | 135 | 155 | 44 | 12 |
| Q4 2021 | 66 | 139 | 139 | 54 | -10 |
| Q1 2022 | 68 | 155 | 140 | 42 | 6 |
| Q2 2022 | 57 | 154 | 154 | 44 | 11 |
Hedge funds changes in Neurocrine Biosciences stock options (Q3 2017 – Q2 2022)
| Q3 2017 | 37,276,000 | 23,176,000 |
|---|---|---|
| Q4 2017 | 30,823,000 | 39,555,000 |
| Q1 2018 | 68,763,000 | 58,560,000 |
| Q2 2018 | 73,065,000 | 69,299,000 |
| Q3 2018 | 60,823,000 | 84,069,000 |
| Q4 2018 | 82,494,000 | 53,618,000 |
| Q1 2019 | 108,025,000 | 77,120,000 |
| Q2 2019 | 73,692,000 | 48,623,000 |
| Q3 2019 | 61,368,000 | 58,144,000 |
| Q4 2019 | 93,855,000 | 56,756,000 |
| Q1 2020 | 62,401,000 | 53,447,575 |
| Q2 2020 | 76,094,000 | 76,364,000 |
| Q3 2020 | 40,536,000 | 135,663,600 |
| Q4 2020 | 39,818,000 | 116,332,000 |
| Q1 2021 | 850,000,068,530,000 | 554,000,051,586,000 |
| Q2 2021 | 83,776,000 | 54,568,000 |
| Q3 2021 | 89,391,000 | 623,000,036,323,000 |
| Q4 2021 | 44,644,000 | 554,000,051,969,000 |
| Q1 2022 | 89,633,000 | 609,079,510,000 |
| Q2 2022 | 110,917,000 | 37,208,000 |